AI-based analysis to find subgroups in adults with type 1 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This ambispective observational project will combine retrospective and prospective clinical data and continuous glucose monitoring (CGM) metrics from about 800 adults with type 1 diabetes followed at Hospital de la Santa Creu i Sant Pau. Artificial intelligence clustering methods will be applied to clinical and glucometric features to identify potential subgroups and characterize their profiles. Secondary analyses will examine cluster stability over 1–3 years, the variables driving cluster membership, and whether clusters predict diabetes-related complications. Participation requires only consent to access existing electronic medical records and CGM platform data, with no additional visits or tests.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Individuals with type 1 diabetes (T1D) aged 18 years or older.
* T1D individuals expected to have regular follow-up at the Endocrinology and Nutrition Department of Hospital de la Santa Creu i Sant Pau.
* Users of continuous glucose monitoring (CGM) systems for at least the last 6 months of 2024.
* Willingness and ability to provide written informed consent to participate in the study (by the patient or his/her representative).

Exclusion Criteria:

* Presence of severe comorbidities or medical conditions that, in the investigator's judgment, could interfere with participation in the study or the interpretation of results. This circumstance is expected to be exceptional, as the study aims to be as inclusive as possible.

Where it's running

• Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona 08041
  Barcelona, Barcelona, Spain Recruiting

Study contacts

• Principal investigator: Rosa M Corcoy — Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
• Study coordinator: Eva Safont, MD
• Email: esafont@santpau.cat
• Phone: +34686203964

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• VV-14300: a gene therapy approach for adults with type 1 diabetes not well controlled on an automated insulin system

  This trial tests VV-14300 in adults with type 1 diabetes who aren’t reaching their blood sugar goals despite using an automated insulin delivery system.

  Recruiting Phase 1/2 Kriya Therapeutics, Inc. · Toronto and 1 other locations · NCT07831798

• New gene therapies VV-14299 and VV-14300 for adults with Type 1 Diabetes failing automated insulin delivery

  This study tests VV-14299 and VV-14300, or VV-14300 alone, in adults with long-standing Type 1 Diabetes whose blood sugar remains poorly controlled despite using an automated insulin delivery system.

  Recruiting Phase 1/2 Kriya Therapeutics, Inc. · Melbourne · NCT07829302

• Oral verapamil in newly diagnosed children and teens with type 1 diabetes

  This study tests whether taking verapamil by mouth can help preserve pancreatic beta cells and reduce insulin needs in kids and teens with recently diagnosed type 1 diabetes.

  Recruiting Phase 2/3 Ain Shams University · Cairo · NCT07804849

• Preventing device-related skin rashes in kids with type 1 diabetes using hydrocolloid vs silicone patches

  This study tests whether silicone-based or hydrocolloid patches help prevent recurring skin irritation from insulin pumps or CGMs in children and teens with type 1 diabetes.

  Recruiting Steno Diabetes Center Copenhagen · Copenhagen · NCT07767461

• AI-assisted remote insulin pump optimization for people with type 1 diabetes

  This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.

  Recruiting The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT07732777

• Near-sensor insulin delivery with CGM in people with type 1 diabetes

  A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.

  Recruiting Early Phase 1 ClinSurge Research · Toronto, Ontario · NCT07655076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.